Hyphens Pharma prices IPO at S$0.26 a share to raise S$13.5m
The company made a net profit of S$6m in 2017, up 16% from 2016 as revenue rose 12% to S$113m
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
HYPHENS Pharma International, which sells specialty pharmaceutical products, is seeking to raise S$13.5 million in net proceeds ahead of a listing on the Singapore Exchange's (SGX) Catalist board.
Hyphens is offering a total of 29.6 million shares (9.9 per cent of the company) at S$0.26 apiece. Cornerstone investors will take up another 10.1 per cent stake in Hyphens.
Copyright SPH Media. All rights reserved.
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
